Menagen Pharmaceutical Industries has made a significant investment of over OMR20 million in building a state-of-the-art factory on a 12,000 square meter plot in the Rusayl Industrial Area in Muscat, Oman. The factory adheres to strict Ministry of Health and FDA regulations, as well as European Medicines Agency (EMA) standards. It is the first of its kind in the Middle East to manufacture specialized medications and medications for rare diseases. The inauguration of the factory was sponsored by Dr. Hilal bin Ali Al Sabti, Minister of Health, and is a major step towards enhancing pharmaceutical security in Oman.
The Menagen Pharmaceutical Industries Factory aims to localise the pharmaceutical industry in the Middle East and North Africa region, revolutionizing the industry by providing innovative and life-saving medications. The total project cost is expected to exceed OMR30 million in the next phases. The factory will play a critical role in strengthening the national economy, creating employment opportunities, advancing scientific research, and attracting skilled professionals to the region. Additionally, it emphasizes cooperation between the public and private sectors to achieve common objectives, showcasing a commitment to developing human capital and fostering innovation.
The factory will focus on producing medications specialized in genetic diseases, metabolic diseases, hereditary blood diseases, kidney diseases, and various types of cancer medications. It will address the healthcare needs of Oman and the wider region. The establishment includes a development and innovation center, the first of its kind in the Middle East, which will facilitate preliminary studies and research, in partnership with Sultan Qaboos University’s Centre for Medical Research and Permanent Cooperation. This partnership aims to enhance drug discovery and development processes in Oman, highlighting a dedication to advancing medical research and enhancing health security in the region.
The pharmaceutical industry in Oman is witnessing significant growth, with Menagen Pharmaceutical Industries leading the way with cutting-edge technologies and strategic partnerships. The factory opening signifies the government’s commitment to supporting the medical sector and creating a favorable environment for industry development. The collaboration between public and private entities in achieving common goals is evident in the establishment of this factory, which is expected to have a transformative impact on the healthcare landscape in Oman and beyond.
The inauguration event was attended by high-ranking officials, ministers, and dignitaries, underlining the importance of the factory in the region’s healthcare ecosystem. Menagen Pharmaceutical Industries is poised to be a leader in providing advanced pharmaceutical solutions that enhance quality of life and contribute to health security in the Middle East and North Africa. The factory is poised to contribute significantly to the region’s economic growth, job creation, and research and development activities, solidifying its position as a pioneering institution in the field of pharmaceuticals.
In conclusion, Menagen Pharmaceutical Industries’ factory opening in Muscat marks a milestone in the region’s pharmaceutical industry, setting a new standard for innovation and advanced medical solutions. The factory’s commitment to producing medications for rare and chronic diseases underscores its dedication to improving patient outcomes and advancing medical research. With cutting-edge facilities and strategic partnerships, Menagen Pharmaceutical Industries is well-positioned to lead the way in shaping the future of healthcare in the Middle East and North Africa, driving economic growth and innovation in the region’s medical sector.
